Servier, Pieris launch up to $1.8B immuno-oncology alliance

Servier will partner with Pieris Pharmaceuticals to co-develop Pieris’ preclinical dual-checkpoint inhibitor PRS-332 and up to seven other immuno-oncology bispecific drug candidates in a collaboration that could generate up to €1.7 billion ($1.8 billion) for Pieris.

Pieris and Servier have agreed to initially pursue five bispecific therapeutic programs led by PRS-332, a potentially best-in-class programmed cell death protein 1 (PD-1)-targeting bispecific checkpoint inhibitor. [Read more]